News headlines about Celldex Therapeutics (NASDAQ:CLDX) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Celldex Therapeutics earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 45.820276127883 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Here are some of the news headlines that may have effected Accern’s rankings:

Shares of Celldex Therapeutics (NASDAQ CLDX) traded down 0.64% during midday trading on Thursday, hitting $3.10. 787,634 shares of the company were exchanged. The company’s 50 day moving average price is $2.70 and its 200 day moving average price is $2.77. Celldex Therapeutics has a one year low of $2.20 and a one year high of $5.02. The firm’s market cap is $397.86 million.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.05. The company had revenue of $3.83 million for the quarter, compared to analyst estimates of $1.21 million. Celldex Therapeutics had a negative return on equity of 51.87% and a negative net margin of 1,318.94%. The business’s revenue was up 175.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.32) earnings per share. Equities analysts expect that Celldex Therapeutics will post ($1.04) EPS for the current year.

CLDX has been the topic of a number of recent research reports. Aegis reiterated a “buy” rating on shares of Celldex Therapeutics in a research note on Thursday, June 29th. Zacks Investment Research upgraded Celldex Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 target price on the stock in a research note on Tuesday, July 11th. BidaskClub cut Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Monday, July 24th. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Celldex Therapeutics in a research note on Tuesday, August 1st. Finally, ValuEngine cut Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $5.88.

ILLEGAL ACTIVITY NOTICE: This piece was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/10/12/celldex-therapeutics-cldx-earning-somewhat-positive-press-coverage-report-finds.html.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

Insider Buying and Selling by Quarter for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Stock Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related stocks with our FREE daily email newsletter.